Safety and Effectiveness of Insulin Detemir in Different Age-Groups in the A1chieve Study
Open Access
- 14 May 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 4 (1), 77-90
- https://doi.org/10.1007/s13300-013-0021-3
Abstract
Diabetes therapy should balance glycemic control with risk of adverse events. This sub-analysis of the A1chieve study evaluated clinical safety and effectiveness of insulin detemir in different age-groups (≤40 years, >40–65 years, and >65 years) of insulin-experienced and insulin-naïve people with type 2 diabetes.This publication has 23 references indexed in Scilit:
- The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countriesDiabetes, Obesity and Metabolism, 2012
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or HypoglycemiaDiabetes Care, 2008
- Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studiesDiabetes, Obesity and Metabolism, 2007
- Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetesDiabetes, Obesity and Metabolism, 2006
- Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 DiabetesClinical Therapeutics, 2006
- A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 DiabetesDiabetes Care, 2006
- Guidelines for Improving the Care of the Older Person with Diabetes MellitusJournal of the American Geriatrics Society, 2003
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990